Mirati Therapeutics P/E 2024

Mirati Therapeutics Aktienanalyse

What does Mirati Therapeutics do?

Mirati Therapeutics Inc is a biotechnology company based in San Diego, California, that focuses on the discovery and development of personalized therapies for cancer. The company was founded in 1995 and originally focused on developing drugs for the treatment of inflammatory diseases. However, in 2012, the company changed its strategy and began to focus on cancer therapies. Mirati Therapeutics' business model is based on the discovery and development of drugs for cancer patients with specific genetic mutations or abnormalities. The company utilizes new insights in cancer genomics to develop targeted therapeutic approaches tailored to the specific needs of cancer patients. The company operates in three different business areas: preclinical research, clinical development, and commercial products. In the preclinical research area, the company focuses on investigating new target candidates and identifying potential drugs for the treatment of cancer. Clinical development involves conducting clinical trials to evaluate the effectiveness and safety of drugs in relation to specific types of cancer. The company also works on marketing and selling commercial products that are already approved on the market and used for the treatment of cancer. One of Mirati Therapeutics' products is the drug Adagrasib, a treatment for patients with advanced non-small cell lung cancer (NSCLC) and specific genetic mutations. Adagrasib aims to inhibit the activity of KRAS, an oncogene that is overexpressed in many types of cancer. The company also has other drugs in the pipeline that are still in preclinical or clinical development. Mirati Therapeutics has partnerships with other companies in the biotech and pharmaceutical industries to advance the discovery and development of new therapies. In 2020, the company announced a strategic collaboration with the pharmaceutical company Amgen to combine Amgen's KRAS inhibitor portfolio with Mirati's and receive milestone payments. The company works closely with the FDA and other regulatory authorities to obtain approval for new drugs and demonstrate the safety and efficacy of its products. The company has made significant progress in the development of personalized cancer therapies in recent years and hopes to be able to help even more patients in the future. In summary, Mirati Therapeutics Inc is an innovative biotechnology company that focuses on the discovery and development of personalized cancer therapies. The company collaborates closely with other industry partners to develop and bring new drugs to the market. Mirati Therapeutics strives to improve the lives of cancer patients and hopes to offer even more innovative therapies in the future. Mirati Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Mirati Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Mirati Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Mirati Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Mirati Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Mirati Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Mirati Therapeutics stock

What is the price-to-earnings ratio of Mirati Therapeutics?

The price-earnings ratio of Mirati Therapeutics is currently -5.06.

How has the price-earnings ratio of Mirati Therapeutics changed compared to last year?

The price-to-earnings ratio of Mirati Therapeutics has increased by 93.13% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Mirati Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Mirati Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Mirati Therapeutics affect the company?

An increase in the price-earnings ratio of Mirati Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Mirati Therapeutics affect the company?

A decrease in the price-earnings ratio of Mirati Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Mirati Therapeutics?

Some factors that influence the price-earnings ratio of Mirati Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Mirati Therapeutics pay?

Over the past 12 months, Mirati Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mirati Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Mirati Therapeutics?

The current dividend yield of Mirati Therapeutics is .

When does Mirati Therapeutics pay dividends?

Mirati Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mirati Therapeutics?

Mirati Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Mirati Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mirati Therapeutics located?

Mirati Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mirati Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mirati Therapeutics from 11/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/6/2024.

When did Mirati Therapeutics pay the last dividend?

The last dividend was paid out on 11/6/2024.

What was the dividend of Mirati Therapeutics in the year 2023?

In the year 2023, Mirati Therapeutics distributed 0 USD as dividends.

In which currency does Mirati Therapeutics pay out the dividend?

The dividends of Mirati Therapeutics are distributed in USD.